# Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

> **NCT00267488** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (actual)

## Conditions studied

- Neoplasms, Endometrial
- Endometrial Cancer

## Interventions

- **DRUG:** topotecan

## Key facts

- **NCT ID:** NCT00267488
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2012-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267488, "Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00267488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*